RxDoctor Payments Data

Jill Covert

Family · Akron, OHNPI 1295487775

Payments from drug & device makers

$5,711in general payments, 2019–2025

Across 286 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$630
  • Ardelyx, Inc.$383
  • Takeda Pharmaceuticals U.S.A., Inc.$360
  • Madrigal Pharmaceuticals$348
  • QOL Medical, LLC$315
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,49396%
  • Education$2174%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,711 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$30,525
Medicare patients
292
Services billed
335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide18$19,597
SutabSod Sulf/Pot Chloride/Mag Sulf71$11,273
Mesalamine27$9,351
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates109$7,051
Pantoprazole Sodium171$2,427
Peg3350-Sod Sul-Nacl-Kcl-Asb-CPeg3350/Sod Sul/Nacl/Kcl/Asb/C32$2,000
Omeprazole174$1,839
Dicyclomine Hcl60$1,405
CholestyramineCholestyramine (With Sugar)15$771
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl35$567
Colestipol Hcl13$487
Ondansetron Hcl250$317
Atorvastatin Calcium32$274
Losartan Potassium19$216
Levothyroxine Sodium16$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,424$19,59718 claims
Braintree Laboratories, Inc.Sutab$30$11,27371 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →